Johnson Financials

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Johnson Johnson Earnings before Tax are increasing as compared to previous years. The last year's value of Earnings before Tax was reported at 17.67 Billion. The current Average Equity is estimated to increase to about 73.4 B, while Market Capitalization is estimated to decrease to under 345.3 B. Use fundamental data analysis to validate all available fundamentals of Johnson Johnson to find out if markets are presently mispricing the organization. We found thirty-eight available reported financial drivers for Johnson Johnson, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Johnson Johnson financials, including its Total Debt, Market Capitalization and the relationship between Gross Profit and Short Ratio . Given that Johnson Johnson has Price to Earning of 21.61 , we strongly advise you confirm Johnson Johnson regular market performance to make sure the company can sustain itself down the road. Use Johnson Johnson to protect your portfolios against small markets fluctuations. The stock experiences unexpected downward movement. The market is reacting to new fundamentals. Check odds of Johnson Johnson to be traded at $114.62 in 30 days.
View Fundamentals For
With this module, you can determine Johnson financials for your investing period. You should be able to track the changes in Johnson Johnson individual fundamental values over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Chance of Financial Distress

Johnson Johnson has less than 12 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Johnson Johnson Company Summary

Johnson Johnson competes with Eli Lilly, Novartis, Gilead Sciences, Pfizer, and Merck. Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 132200 people.
Foreign Associates
Healthcare, Drug Manufacturers - General
InstrumentUSA Stock View All
ExchangeBATS Exchange
CIK Number0000200406
RegionNorth America
LocationNew Jersey; U.S.A
Business AddressOne Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States
IndustryDrug Manufacturers?General
Phone732 214 0332
CurrencyUSD - US Dollar

Johnson Johnson Key Financial Ratios

Johnson Financial Ratios Relationships

Johnson Johnson is rated below average in debt to equity category among related companies. It is rated second overall in retained earnings category among related companies reporting about  2,161,145,263  of Retained Earnings per Debt to Equity.

Johnson Johnson Systematic Risk

The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Johnson Johnson correlated with the market. If Beta is less than 0 Johnson Johnson generally moves in the opposite direction as compared to the market. If Johnson Johnson Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Johnson Johnson is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Johnson Johnson is generally in the same direction as the market. If Beta > 1 Johnson Johnson moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Johnson Johnson Thematic Clasifications

Corona Opportunity Idea
Corona OpportunityView
Dividend Beast Idea
Dividend BeastView
Baby Boomer Prospects Idea
Baby Boomer ProspectsView
Drugs Idea
Investor Favorites Idea
Investor FavoritesView
Compulsion Idea

Johnson Johnson March 28, 2020 Opportunity Range

Please see Risk vs Return Analysis. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page